NMT cP12

Drug Profile

NMT cP12

Alternative Names: NMT-cP12

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeoMatrix Therapeutics
  • Class Peptides; Skin disorder therapies
  • Mechanism of Action Platelet-derived growth factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Burns
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Burns

Most Recent Events

  • 31 Oct 2017 NMT cP12 receives Fast Track designation for Burns in USA before October 2017
  • 31 Oct 2017 NMT cP12 receives Orphan Drug status for Burns in USA before October 2017
  • 31 Oct 2017 NeoMatrix plans a phase I trial for Burns (Healthy volunteers) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top